Search | TVST | ARVO Journals

Showing 1 – 15 of 15

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Phase I/IIa study examining the safety and tolerability of single and multiple rising intravitreal doses of BI 836880 in patients with wAMD

Oliver Zeitz; Albert Edwards; Allen Hu; Brian Berger; Gudrun Simons; michael ehrlich; Daniel Peter; Sobha Sivaprasad

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3124. doi:

Clinical Trials December 2021

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

PDF

Pravin U. Dugel; Arshad M. Khanani; Brian B. Berger; Sunil Patel; Mitchell Fineman; Glenn J. Jaffe; Petra Kozma-Wiebe; Jeffrey Heier
TAGS: diabetic macular edema, injections, plasma kallikrein, safety, inflammation, surrogate endpoints, eye
Trans. Vis. Sci. Tech.. 2021; 10(14):28. doi: https://doi.org/10.1167/tvst.10.14.28

Includes: Supplemental Content

Clinical Trials December 2021

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

PDF

Victor H. Gonzalez; Brian Berger; Roger Goldberg; Carmelina M. Gordon; Rahul N. Khurana; Raymund Angeles; Naveed Shams
TAGS: anti-vascular endothelial growth factor therapy, exudative age-related macular degeneration, persistence, phase 1 clinical trials, safety, intravitreal injections, cohort studies, endoglin, eye
Trans. Vis. Sci. Tech.. 2021; 10(14):27. doi: https://doi.org/10.1167/tvst.10.14.27

Includes: Supplemental Content

Clinical and Epidemiologic Research May 2018

A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema

PDF

Jeremy D. Gale; Brian Berger; Steven Gilbert; Serghei Popa; Marla B. Sultan; Ronald A. Schachar; Douglas Girgenti; Christelle Perros-Huguet
TAGS: diabetic macular edema, ranibizumab, safety
Invest. Ophthalmol. Vis. Sci.. 2018; 59(6):2659-2669. doi: https://doi.org/10.1167/iovs.17-22731

Includes: Supplemental Content

ARVO Annual Meeting Abstract September 2016

Effect of selective oral inhibition of CCR2/5 chemokine receptors compared to intravitreal ranibizumab on diabetic macular edema (DME)

Brian B Berger; Jeremy Gale; Steven Gilbert; Sergei Popa; Marla Sultan; Ronald Schachar; Rob Webster; Christelle Perros-Huguet

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2109. doi:

ARVO Annual Meeting Abstract June 2015

Efficacy of RTH258 (ESBA1008), an Anti-VEGF Agent, Applied by Microvolume Injection or Infusion in Subjects with Neovascular AMD

Brian B Berger; Susan E Yanni; Andreas Wenzel; Andreas Weichselberger; Jean Pierre Hubschman

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):821. doi:

ARVO Annual Meeting Abstract April 2014

Demographics and Baseline Characteristics of the iDEAL Study: A Randomized, Multi-center, Phase II Study of the safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCO-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of the FoveAL Center

Yasir Sepah; Diana V Do; David Callanan; Victor H Gonzalez; Lawrence Halperin; Brian B Berger; Mostafa Saad Hanout; Peter Hnik; Quan Dong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1758. doi:

ARVO Annual Meeting Abstract April 2014

The Course of Eyes with Vitrectomy Prior to Enrollment in a Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser for Diabetic Macular Edema

Brian B Berger; Diabetic Retinopathy Clinical Research Network

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1771. doi:

ARVO Annual Meeting Abstract June 2013

Phase I, Masked, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Studies Evaluating Systemic and Ocular Safety, Tolerability, and Visual Acuity Effects of RN6G (PF-04382923) in Subjects with Dry, Age-Related Macular Degeneration (ARMD)

Brian Berger; Pamela Garzone; Ivana Gunderson; Philip Fanning; Gilbert Wong; Kai Liao; Steven Hua; John Lin

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4505. doi:

Clinical and Epidemiologic Research December 2012

Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy: Heidelberg Spectralis Optical Coherence Tomography

PDF

Kakarla V. Chalam; Susan B. Bressler; Allison R. Edwards; Brian B. Berger; Neil M. Bressler; Adam R. Glassman; Sandeep Grover; Shailesh K. Gupta; Jared S. Nielsen; for the Diabetic Retinopathy Clinical Research Network
TAGS: diabetes mellitus, diabetes mellitus, type 2, diabetic retinopathy, optical coherence tomography, retinal diseases, eye, cohort studies, volume
Invest. Ophthalmol. Vis. Sci.. 2012; 53(13):8154-8161. doi: https://doi.org/10.1167/iovs.12-10290

ARVO Annual Meeting Abstract March 2012

Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy as Measured by Heidelberg Spectralis Optical Coherence Tomography

Brian B. Berger; Diabetic Retinopathy Clinical Research Network

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2872. doi:

ARVO Annual Meeting Abstract March 2012

A Phase I/II Study of Oral Pazopanib, a Receptor Tyrosine Kinase Inhibitor, in Neovascular Age Related Macular Degeneration

Jason S. Slakter; Michael J. Tolentino; Brian B. Berger; Joel Pearlman; Robert Noble; Li Ye; Chun-Fang Xu; Ronald P. Danis; Megan McLaughlin; Robert Kim

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2038. doi:

ARVO Annual Meeting Abstract March 2012

Multicenter Phase 1 Clinical Trial Targeting Tissue Factor for the Treatment of Neovascular AMD

John A. Wells, III; Brian B. Berger; Christine Gonzales; Victor H. Gonzales; David L. Johnson; Brian D. Sippy; Manju Soni

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):450. doi:

ARVO Annual Meeting Abstract April 2011

Expanded Two-year Follow Up Of A Randomized Trial Evaluating Ranibizumab Plus Prompt Or Deferred Laser Or Triamcinolone Plus Prompt Laser For Diabetic Macular Edema

Brian B. Berger; Diabetic Retinopathy Clinical Research Network

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5335. doi:

ARVO Annual Meeting Abstract April 2011

Single Ascending Doses of DARPin®, MP0112, Show Potential for Quarterly Dosing in DME

Manjula Patel; Brian B. Berger; Jeffrey S. Heier; David M. Brown; Peter A. Campochiaro; Michael T. Stumpp

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):582. doi:

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Phase I/IIa study examining the safety and tolerability of single and multiple rising intravitreal doses of BI 836880 in patients with wAMD

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema

Effect of selective oral inhibition of CCR2/5 chemokine receptors compared to intravitreal ranibizumab on diabetic macular edema (DME)

Efficacy of RTH258 (ESBA1008), an Anti-VEGF Agent, Applied by Microvolume Injection or Infusion in Subjects with Neovascular AMD

The Course of Eyes with Vitrectomy Prior to Enrollment in a Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser for Diabetic Macular Edema

Phase I, Masked, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Studies Evaluating Systemic and Ocular Safety, Tolerability, and Visual Acuity Effects of RN6G (PF-04382923) in Subjects with Dry, Age-Related Macular Degeneration (ARMD)

Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy: Heidelberg Spectralis Optical Coherence Tomography

Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy as Measured by Heidelberg Spectralis Optical Coherence Tomography

A Phase I/II Study of Oral Pazopanib, a Receptor Tyrosine Kinase Inhibitor, in Neovascular Age Related Macular Degeneration

Multicenter Phase 1 Clinical Trial Targeting Tissue Factor for the Treatment of Neovascular AMD

Expanded Two-year Follow Up Of A Randomized Trial Evaluating Ranibizumab Plus Prompt Or Deferred Laser Or Triamcinolone Plus Prompt Laser For Diabetic Macular Edema

Single Ascending Doses of DARPin®, MP0112, Show Potential for Quarterly Dosing in DME

To View More...

You must be signed into an individual account to use this feature.